Skip to content
BOE-A-2026-12611 ·11 June 2026 ·Royal Decree Medium impact
Administrative

Pharmaceutical companies to implement electronic medication registration by March

Royal Decree 468/2026 amends RD 1345/2007 to require electronic registration of industrially produced human medicines. A new Additional Provision 7 sets a three-month implementation period from the decree's entry into force, aiming to modernise control and improve product traceability (arts. 81.1, 84-86, disp. ad. 7).

In 3 key points

  1. Electronic submission of authorisation applications is required (disposición adicional 7)
  2. Three-month period to adapt processes from date of entry into force (disposición adicional 7)
  3. Amends Articles 81.1, 84 to 86 and Additional Provisions 5 and 6 (art. 81.1, 84-86, disp. adic. 5 y 6)

How it affects those involved

Pharmaceutical manufacturers must transition to electronic submission processes within three months of implementation. Health authorities will receive digital applications, enhancing traceability and operational efficiency. Applicants without electronic access will no longer be able to submit physical applications. The change has no impact on end users or distribution centres.

Lifecycle

2026-06-11PublishedPublished in the BOE
2026-07-11Into forceComes into force (disposición final primera)
Official text Based on BOE data (boe.es). Information, not advice.

Does this provision affect you?

The administrative team reviews your specific situation.

Talk to the administrative team
This analysis is informational only and does not constitute legal advice or create a client-adviser relationship. BM Consulting.
Email
Contact